Drugs / AX-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05965089 | Apr 2023 → Jul 2024 | psoriasis | Arxx Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AX-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05965089 ↗ |
| Route | Other | “The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of AX-202 infusion.” NCT05965089 ↗ |